These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27248324)

  • 1. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
    Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
    Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
    Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
    Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
    Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
    Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
    Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
    Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation.
    Zhang T; Cui GB; Zhang J; Zhang F; Zhou YA; Jiang T; Li XF
    Oncol Rep; 2010 Dec; 24(6):1683-9. PubMed ID: 21042768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
    Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP
    Cancer Res; 2009 Oct; 69(19):7644-52. PubMed ID: 19789349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
    Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
    PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
    Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
    Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
    Hemström TH; Sandström M; Zhivotovsky B
    Int J Cancer; 2006 Sep; 119(5):1028-38. PubMed ID: 16570272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
    Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
    Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
    Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
    Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.